Education
About Us
Working with TipRanks
Follow Us
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
CNTA Stock Chart & Stats
$26.20
-$0.91(-5.25%)
At close: 4:00 PM EST
$26.20
-$0.91(-5.25%)
Day’s Range― - ―
52-Week Range$9.60 - $30.58
Previous CloseN/A
Volume658.98K
Average Volume (3M)1.28M
Market Cap
$3.52B
Enterprise Value$3.65B
Total Cash (Recent Filing)$246.21M
Total Debt (Recent Filing)$118.26M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Mar 26, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding146,075,740
10 Day Avg. Volume929,415
30 Day Avg. Volume1,277,863
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.78
Price to Sales (P/S)0.00
P/FCF Ratio-13.49
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue243.36
Enterprise Value/Gross Profit247.13
Enterprise Value/Ebitda-16.06
Forecast
1Y Price Target
$43.29Price Target Upside65.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.61
Revenue Forecast (FY)$2.47M
Bulls Say, Bears Say
Bulls Say
Clinical-stage Pipeline Progress (OX2R Agonists)Advancing ORX750 into a registrational program marks a structural de-risking milestone for Centessa’s neuroscience franchise. Moving from exploratory to registrational trials increases the likelihood of later regulatory value creation and directs R&D resources toward a coherent, higher-priority commercial pathway over the next 2–3 years.
High Reported Gross ProfitabilitySustained gross margins near 94% indicate collaboration and product-related revenues incur low direct costs, implying that if Centessa converts pipeline successes to recurring sales or higher-value licensing, incremental revenue could flow to the bottom line efficiently and support long-term margin sustainability once commercialized.
Improved Funding Flexibility Via ATM AmendmentAccess to a $250M ATM increases strategic optionality to smooth financing over time, reducing acute refinancing risk. For a clinical-stage biotech with ongoing trials, this structural flexibility helps maintain program funding, enabling multi-year R&D plans without forcing large, single-event capital raises.
Bears Say
Large And Persistent Cash BurnVery negative operating and free cash flow reflects ongoing funding of multiple clinical programs and is a durable constraint on the business. Continued burn necessitates periodic external financing, increasing execution risk if capital markets tighten and potentially delaying programs if funding is constrained.
Deep Unprofitability And Negative MarginsLarge operating losses show the company is far from self-sustaining while clinical-stage, meaning profitability depends on successful clinical outcomes and future commercialization. This structural deficit limits reinvestment capacity and increases reliance on external capital to fund R&D and regulatory milestones over the medium term.
Equity Erosion And Ongoing Dilution RiskDeclining equity alongside heavy losses signals cumulative dilution and capital consumption. Coupled with recent ADS offerings and ATM capacity, shareholders face structural dilution risk as the company repeatedly taps markets to fund operations until products generate sustainable cash flow.
Centessa Pharmaceuticals News
CNTA FAQ
What was Centessa Pharmaceuticals’s price range in the past 12 months?
Centessa Pharmaceuticals lowest stock price was $9.60 and its highest was $30.58 in the past 12 months.
What is Centessa Pharmaceuticals’s market cap?
Centessa Pharmaceuticals’s market cap is $3.52B.
When is Centessa Pharmaceuticals’s upcoming earnings report date?
Centessa Pharmaceuticals’s upcoming earnings report date is Mar 26, 2026 which is in 21 days.
How were Centessa Pharmaceuticals’s earnings last quarter?
Centessa Pharmaceuticals released its earnings results on Nov 05, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.022.
Is Centessa Pharmaceuticals overvalued?
According to Wall Street analysts Centessa Pharmaceuticals’s price is currently Undervalued.
Does Centessa Pharmaceuticals pay dividends?
Centessa Pharmaceuticals does not currently pay dividends.
What is Centessa Pharmaceuticals’s EPS estimate?
Centessa Pharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does Centessa Pharmaceuticals have?
Centessa Pharmaceuticals has 146,075,740 shares outstanding.
What happened to Centessa Pharmaceuticals’s price movement after its last earnings report?
Centessa Pharmaceuticals reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went down -5.139%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals?
Currently, no hedge funds are holding shares in CNTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Centessa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.29 (65.23% Upside)
$43.29 (65.23% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.20%
12-Months-Change
Fundamentals
Return on Equity
-60.46%
Trailing 12-Months
Asset Growth
-26.47%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
CNTA Stock 12 Month Forecast
Average Price Target
$43.29
▲(65.23% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
Ownership Overview
1.27% Insiders
11.90% Mutual Funds
73.72% Other Institutional Investors
3.46% Public Companies and
Individual Investors